Document is current

Article History

Received: 20 September 2019

Accepted: 3 February 2020

First Online: 15 February 2020

Compliance with ethical standards

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

: VP: Ipsen, ITG, Bayer (honoraria/consultant); Ipsen (remuneration for travel, accommodation, expenses)RS: Ipsen, Novartis, Mylan (honoraria)CT: Ipsen, Novartis, Advanced Accelerator Applications (honoraria)CG: Norgine (remuneration for consultancy); Ipsen, Novartis, and Iason (remuneration for travel, accommodation, expenses)SB: NoneTS: Ipsen (honoraria, remuneration for consultancy, travel, accommodation, expenses)AL: Ipsen, Pfizer, Merck (remuneration for speaker’s bureau); Ipsen, Pfizer, Novartis, AAA, Bayer, Delcath, SirTex (remuneration for travel, accommodation, expenses); EISAI, Nutricia (remuneration for consultancy)FC: Nalgene (remuneration for advisory board member/board of directors); Advanced Accelerator Applications, Bayer (grant recipient); GEHC, Bayer, Advanced Accelerator Applications, Novartis, Ipsen (remuneration for speaker’s bureau); GEHC, Bayer, Advanced Accelerator Applications, Novartis, Ipsen, Cyclopharma, Norgine (remuneration for travel, accommodation, expenses)KS: Ipsen, Shire (honoraria); Ipsen, Novartis, Shire, Eisa (remuneration for consultancy)EB: Ipsen, Novartis, Advanced Accelerator Applications, Pfizer (honoraria, remuneration for consultancy, grant recipient)XMTT and AH: Ipsen employeesCD: Ipsen (Honoraria, consultancy fees)LB: Ipsen, Advanced Accelerator Applications (honoraria, remuneration for consultancy, grant recipient)

: Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6 months and ending 5 years after publication; after this time, only raw data may be available.

: France: E. Baudin, F. Courbon; Germany: V. Prasad, K. Scheidhauer; Italy: S. Baldari, C.M. Grana; L. Bodei (now USA); UK: A. Lamarca, T. Shah, R. Srirajaskanthan, C. Toumpanakis, J. Valle